ST-2; a Non-invasive Fibrosis Marker for Chronic Hepatitis B

The Ability of Prediction of Fibrosis for ST-2 as a Non-invasive Marker in Chronic Hepatitis B

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01633554

Enrollment

Registered

2012-07-04

Start date

2011-01-31

Completion date

2012-09-30

Last updated

2012-07-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sequela of Chronic Liver Disease

Keywords

ST-2, IL-33, prediction, fibrosis, hepatitis B

Brief summary

IL-33 is a recently identified number of the IL-1 family. Hepatic over-expression of IL-33 has been recently linked to liver fibrosis. ST-2 exerts pro-inflammatory effects of IL-33. We aimed to determine ability of ST2 to predict fibrosis in chronic hepatitis B.

Detailed description

ST-2 is an IL-1 receptor family member and exists in both a membrane-bound isoform and a soluble (sST2) isoform. It has a functional ligand (Interleukin-33) and via ST-2/IL-33 inflammation and immunity is regulated. Hepatic over-expression of IL-33 has been recently linked to liver fibrosis. ST-2 exerts pro-inflammatory effects of IL-33. We aimed to determine ability of ST2 to predict fibrosis in chronic hepatitis B.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Clinical diagnosis of chronic hepatitis B or liver cirrhosis

Exclusion criteria

* Accompanying chronic inflammatory disease

Countries

Turkey (Türkiye)

Contacts

Primary Contactİsmail H KALKAN, MD

drismailster@gmail.com+90 312 437 67 78

Outcome results